Hitoshi Arioka
About
Hitoshi Arioka is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine.
According to data from OpenAlex, Hitoshi Arioka has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 31 papers in Molecular Biology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Hitoshi Arioka's work include Cancer Treatment and Pharmacology (14 papers), Cancer therapeutics and mechanisms (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Hitoshi Arioka is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Cancer therapeutics and mechanisms (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Hitoshi Arioka collaborates with scholars based in Japan, United Kingdom and United States. Hitoshi Arioka's co-authors include Nagahiro Saijo, Kazuto Nishio, Hisao Fukumoto, Tomoyuki Ishida, N Saijo, Fumihiko Kanzawa, Kohei Nishio, Hirokazu Kurokawa, Minoru Fukuda and Kazuya Fukuoka and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and The American Journal of Medicine.
In The Last Decade
Hitoshi Arioka
60 papers receiving 1.1k citations
Peers
Hitoshi Arioka
Kiyoshi Okamoto Japan
Christian Kuntzen United States
Tomohide Tamura Japan
Wei‐Tien Tai Taiwan
Justin Lesch United States
A Wakui Japan
Sachiko Ogasawara Japan
Sang‐Hyun Song South Korea
Isabelle Hennebelle France
Yasutaka Shuno Japan
Citations per year, relative to Hitoshi Arioka Hitoshi Arioka (= 1×)
peers
Kiyoshi Okamoto
Countries citing papers authored by Hitoshi Arioka
Since
Specialization
Citations
This map shows the geographic impact of Hitoshi Arioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hitoshi Arioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hitoshi Arioka more than expected).
Fields of papers citing papers by Hitoshi Arioka
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hitoshi Arioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hitoshi Arioka. The network helps show where Hitoshi Arioka may publish in the future.
Co-authorship network of co-authors of Hitoshi Arioka
This figure shows the co-authorship network connecting the top 25 collaborators of Hitoshi Arioka. A scholar is included among the top collaborators of Hitoshi Arioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hitoshi Arioka. Hitoshi Arioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shimomura, Kyoichi, Hitoshi Arioka, Hirotoshi Iihara, et al.. (2021). LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial. Annals of Oncology. 32. S1339–S1340.
2.
Izawa, Naoki, Takashi Kawaguchi, Tempei Miyaji, et al.. (2020). Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. BMJ Open. 10(12). e041737–e041737.
3.
Cheng, Ann‐Lii, Masatoshi Kudo, Po‐Chin Liang, et al.. (2015). G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Journal of Hepatology. 62. S189–S190.
4.
Inaba, Yoshitaka, Fumihiko Kanai, Takeshi Aramaki, et al.. (2013). A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European Journal of Cancer. 49(13). 2832–2840.
5.
Suzuki, Yasuhiro, Toshiaki Saeki, Kenjiro Aogi, et al.. (2012). A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International Journal of Clinical Oncology. 18(4). 590–597.
6.
Yonemori, Kan, Masashi Ando, Mayu Yunokawa, et al.. (2008). Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. British Journal of Cancer. 100(1). 50–55.
7.
Tatsumi, Yasuaki, Hitoshi Arioka, Shun‐ichi Ikeda, et al.. (2001). Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6. Japanese Journal of Cancer Research. 92(7). 768–777.
8.
Fukuoka, Kazuya, Hitoshi Arioka, Yasuo Iwamoto, et al.. (2001). Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer. 34(3). 451–460.
9.
Fukuoka, Kazuya, Kazuto Nishio, Hisao Fukumoto, et al.. (2000). Ectopic p16ink4 expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. International Journal of Cancer. 86(2). 197–203.
10.
Yokote, Hideyuki, Hitoshi Arioka, Hirokazu Kurokawa, et al.. (1998). The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin. Mutation Research/DNA Repair. 409(3). 147–162.
11.
Ishida, Tomoyuki, et al.. (1997). In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells. Japanese Journal of Cancer Research. 88(11). 1033–1037.
12.
Fukumoto, Hisao, Makoto Nishio, Kazuto Nishio, et al.. (1997). Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo. Japanese Journal of Cancer Research. 88(5). 501–505.
13.
Nishio, Kazuto, et al.. (1997). Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene. Japanese Journal of Cancer Research. 88(2). 108–110.
14.
Nishio, Kazuto, et al.. (1997). Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149. International Journal of Cancer. 72(5). 865–870.
15.
Fukuoka, Kazuya, Jun‐ichi Adachi, Kazuto Nishio, et al.. (1997). p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors. Japanese Journal of Cancer Research. 88(10). 1009–1016.
16.
Tomonari, Akira, Kazuto Nishio, Hirokazu Kurokawa, et al.. (1997). Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene. Biochemical and Biophysical Research Communications. 232(2). 522–527.
17.
Ohira, Tetsuya, Kazuto Nishio, Yuichiro Ohe, et al.. (1996). Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. Journal of Cancer Research and Clinical Oncology. 122(12). 711–715.
18.
Oshita, Fumihiro, Hitoshi Arioka, Yuji Heike, Jun‐ichi Shiraishi, & Nagahiro Saijo. (1995). Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay. Japanese Journal of Cancer Research. 86(2). 233–238.
19.
Ohmatsu, H., Tomohide Tamura, Hiroshi Kunikane, et al.. (1994). A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin. Japanese Journal of Cancer Research. 85(11). 1151–1158.
20.
Tamura, Tomohide, Yasutsuna Sasaki, Kenji Eguchi, et al.. (1994). Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion. Japanese Journal of Cancer Research. 85(10). 1057–1062.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kiyoshi Okamoto Breakdown of academic impact, for papers by Christian Kuntzen Breakdown of academic impact, for papers by Tomohide Tamura Breakdown of academic impact, for papers by Wei‐Tien Tai Breakdown of academic impact, for papers by Justin Lesch Breakdown of academic impact, for papers by A Wakui Breakdown of academic impact, for papers by Sachiko Ogasawara Breakdown of academic impact, for papers by Sang‐Hyun Song Breakdown of academic impact, for papers by Isabelle Hennebelle Breakdown of academic impact, for papers by Yasutaka Shuno